Brooklyn FI LLC Takes Position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)

Brooklyn FI LLC bought a new position in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 594,919 shares of the company’s stock, valued at approximately $677,000. Brooklyn FI LLC owned approximately 0.85% of SELLAS Life Sciences Group as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. State Street Corp boosted its position in shares of SELLAS Life Sciences Group by 30.2% during the 3rd quarter. State Street Corp now owns 174,529 shares of the company’s stock worth $218,000 after purchasing an additional 40,500 shares in the last quarter. XTX Topco Ltd acquired a new position in SELLAS Life Sciences Group during the 3rd quarter worth approximately $78,000. Anson Funds Management LP bought a new position in SELLAS Life Sciences Group in the third quarter worth approximately $992,000. Geode Capital Management LLC grew its stake in SELLAS Life Sciences Group by 17.1% in the third quarter. Geode Capital Management LLC now owns 605,191 shares of the company’s stock valued at $757,000 after acquiring an additional 88,183 shares during the period. Finally, Virtu Financial LLC increased its holdings in shares of SELLAS Life Sciences Group by 24.1% during the third quarter. Virtu Financial LLC now owns 79,241 shares of the company’s stock valued at $99,000 after acquiring an additional 15,398 shares in the last quarter. 17.38% of the stock is currently owned by institutional investors and hedge funds.

SELLAS Life Sciences Group Stock Up 12.0 %

Shares of SLS opened at $1.21 on Thursday. The business’s fifty day moving average is $1.20 and its 200 day moving average is $1.17. SELLAS Life Sciences Group, Inc. has a 12-month low of $0.77 and a 12-month high of $1.84. The stock has a market cap of $85.16 million, a P/E ratio of -1.75 and a beta of 2.43.

SELLAS Life Sciences Group Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.